Naratuximab emtansine (IMGN529) is a CD37-targeted ADC consisting of a humanized IgG1 mAb coupled to the microtubule disruptor DM1. Naratuximab emtansine has high affinity and specificity for CD37, allowing ADC internalization, processing and intracellular release of DM1. Due to its ability to disrupt microtubule assembly, DM1 can subsequently induce cell cycle arrest and apoptosis[1].
Purity:
98.52
CAS Number:
[1607824-64-5]
Target:
Antibody-Drug Conjugates (ADCs),Apoptosis
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
